Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab + Lenalidomide/Dexamethasone in Japanese NDMM
NCT02272803Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2015
- Primary completion
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elotuzumab in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Started Feb 2015; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02272803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02272803.